- MediciNova (NASDAQ:MNOV) is finalizing the protocol of a new Phase 3 program evaluating MN-166 (ibudilast) in patients with secondary progressive multiple sclerosis (MS) without relapse, a subgroup of MS sufferers with no currently available medications to treat their condition.
- The company recently conducted a further analysis of the Phase 2b SPRINT-MS study of MN-166 in patients with progressive MS that showed patients with secondary progressive MS with relapse experienced 46% less risk of disease progression compared to placebo.